Tizanidne Hydrochloride Capsule
Product Images NDC 72162-1862

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 72162-1862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621862)

Label for Tizanidine Hydrochloride Capsules 6 mg, 150 count, relabeled by Bryant Ranch Prepack and manufactured by Alkem Laboratories Ltd. The label includes dosage strength, NDC 72162-1862-2, storage instructions, and a warning that the product is not interchangeable with tizanidine or Zanaflex tablets.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of tizanidine hydrochloride, showing its molecular composition including a chlorinated benzene ring fused with a thiazole and an imidazoline ring, annotated with HCl.*

FDA Label Image

Tiz02 (Tiz02)

A line graph displaying plasma Tizanidine concentration (ng/mL) over time (hours from dosing) for 2 x 4 mg Tizanidine tablets and capsules, with and without food. The graph shows concentration changes from 0 to 24 hours post-dose for four different conditions: tablets with food, tablets without food, capsules with food, and capsules without food.*

FDA Label Image

Tiz03 (Tiz03)

A line graph depicting improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph shows greater improvement for the 16 mg dose compared to 8 mg and placebo, with error bars indicating variability at each time point.*

FDA Label Image

Tiz04 (Tiz04)

A line chart comparing improvement in Ashworth Score over three study time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). It displays two groups, tizanidine (mean dose 28.8 mg) with higher improvement scores and placebo with lower scores, each including error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.